Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
The purpose of this study is to assess the safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic gastroenteropancreatic or pulmonary neuroendocrine Tumors (NET).
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
DRUG: Pasireotide LAR followed by Pasireotide LAR + Everolimus|DRUG: Everolimus followed by Pasireotide LAR + Everolimus
Evaluate safety and tolerability profile of pasireotide LAR in combination with everolimus in patients with advanced metastatic NET, 3 months
Evaluate safety and tolerability of pasireotide LAR and/or everolimus in patients with advanced metastatic NET, 15 months|To assess pharmacokinetic exposures of pasireotide LAR and everolimus during monotherapy and in combination therapy, 15 months|To assess potential drug-drug interactions between pasireotide and everolimus during combination therapy, 12 months|To assess symptom control (bowel movements and flushing episodes) with pasireotide LAR in combination with everolimus in patients with functioning tumors, 15 months|To assess the biochemical response (chromograninA, CgA) to pasireotide LAR in combination with everolimus, 15 months
The purpose of this study is to assess the safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic gastroenteropancreatic or pulmonary neuroendocrine Tumors (NET).